INVESTORS | J. Molner

top of page

picture of a chemistry laboratory

INVESTORS

STOCK EXCHANGE RELEASES

25 Nov. 2025 J. Molner AS Announcement Regarding the Adoption of the Decisions of the Extraordinary General Meeting of Shareholders Without Calling the Meeting

14 Nov. 2025 J. Molner AS launches Clobetasol Propionate Cream USP, 0.05% (Emollient) in the United States

30 Sept. 2025 J. Molner AS 2025 6 months consolidated unaudited interim report

30 Sept. 2025 The subsidiary of J. Molner AS The J. Molner Company OÜ was granted an additional loan

PRESS RELEASES

7 Nov. 2022 Pharmaceutical company J. Molner raised about 700,000 euros in the IPO

27 Oct. 2022 J. Molner Introduction Webinar (English)

19 Oct. 2022 IPO of the pharmaceutical company Molner commences on 24 October

06 Oct. 2022 J. Molner submits first drug to Health Canada

KEY DOCUMENTS

Extraordinary Meeting of Shareholders 2025

Supervisory Board Resolution (Agenda Approval)

J.Molner AS annual general meeting electronic voting form 2025

J.Molner AS annual general meeting power of attorney form 2025

J. Molner AS articles of association

J. Molner AS Consolidated Annual Report 2024

J. Molner AS Consolidated Annual Report 2024

Annual Meeting of Shareholders 2025

Report of the Supervisory Board Regarding Financial Year 2024

Supervisory Board Resolution

J. Molner AS Consolidated Annual Report 2024

J. Molner AS Annual General Meeting of Shareholders Management Board Resolution 2024 (EE)

J.Molner AS annual general meeting electronic voting form 2025

J.Molner AS annual general meeting power of attorney form 2025

J. Molner AS voting protocol of shareholders' decisions

FIRESIDE CHAT - 3 NOV 2022

live from the EBS studio, a conversation with our founder

WEBINAR - 27 OCT 2022

bottom of page